Evidence mapPaperPMID 41758322Full record

ArticleArchives of pharmacal research2026

PBPK modeling of the antidepressant doxepin incorporating CYP2D6 genotype for precision pharmacotherapy.

Joohee Seok, Nahyun Kang, Je Jin Lee, Chang-Keun Cho, Yun Jeong Lee

Abstract read
In one paragraph

Article in Archives of pharmacal research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joohee Seok *Chung-Ang University College of Medicine, Seoul, 06974, Korea.
Nahyun Kang *Chung-Ang University College of Medicine, Seoul, 06974, Korea.
Je Jin LeeChung-Ang University College of Medicine, Seoul, 06974, Korea. jjlee910222@gmail.com.
Chang-Keun ChoSchool of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Yun Jeong LeeCollege of Pharmacy, Dankook University, Cheonan, 31116, Republic of Korea. yunlee@dankook.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxepin, a tricyclic antidepressant, exhibits substantial interindividual variability in pharmacokinetics, mainly attributable to genetic polymorphisms of cytochrome P450 (CYP) enzymes, particularly CYP2D6. Such variability may lead to clinically relevant differences in drug exposure, therapeutic response, and adverse effects when doxepin is used for antidepressant therapy. The present study aimed to develop and validate physiologically based pharmacokinetic (PBPK) models of doxepin and its active metabolite, N-desmethyldoxepin, incorporating CYP2D6 genetic polymorphisms to support precision pharmacotherapy. PBPK models were constructed using PK-Sim

Indexed as

Antidepressive AgentsAntidepressive Agents, TricyclicCytochrome P-450 CYP2D6DoxepinModels, BiologicalPrecision MedicineAdultFemaleGenotypeHumansMaleMiddle AgedPolymorphism, GeneticAntidepressive AgentsAntidepressive Agents, TricyclicCytochrome P-450 CYP2D6DoxepinCYP2D6DoxepinN-desmethyldoxepinPharmacogenomicsPhysiologically based pharmacokinetic modelingPrecision pharmacotherapy

Identifiers

PMID41758322
PMCPMC12999657

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.